Q3 2021 Investor Relations Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Delivering solid results in the quarter; sales +5%, core Oplnc +9%
Group¹
USD million
Q3
Change vs. PY
9M
Change vs. PY
2021
2021
% USD
% cc
% USD
% CC
Net Sales
13,030
6
5
38,397
7
4
Core Operating income
4,467
10
9
12,769
7
4
Operating income
3,233
34
32
9,127
Net Income
2,758
43
41
7,712
29
22
22
18
26
Core EPS (USD)
1.71
13
11
4.88
10
7
EPS (USD)
1.23
45
44
3.44
31
28
Free Cash Flow
4,423
64
10,255
23
1. Core results, constant currencies and free cash flow are non-IFRS measures. Further details regarding non-IFRS measures can be found starting on page 47 of the Condensed Interim Financial Report. All % growth relate to cc unless
otherwise stated.
38 Investor Relations | Q3 2021 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation